Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24038428 | 0.90 | SLC5A1 (0.81) | SLC5A1SLC5A2 | |
| SCHEMBL24038303 | 0.89 | SLC5A1 (0.80) | SLC5A1SLC5A2 | |
| SCHEMBL24037945 | 0.89 | SLC5A1 (0.80) | SLC5A1SLC5A2 | |
| SCHEMBL24037957 | 0.89 | SLC5A1 (0.80) | SLC5A1SLC5A2 | |
| SCHEMBL24037937 | 0.88 | SLC5A1 (0.78) | SLC5A1SLC5A2 | |
| SCHEMBL26550652 | 0.88 | SLC5A1 (0.80) | SLC5A1SLC5A2 | |
| SCHEMBL26550666 | 0.87 | SLC5A1 (0.77) | SLC5A1SLC5A2 | |
| SCHEMBL24030085 | 0.87 | SLC5A1 (0.77) | SLC5A1SLC5A2 | |
| SCHEMBL24037946 | 0.87 | SLC5A1 (0.77) | SLC5A1SLC5A2 | |
| SCHEMBL24038400 | 0.86 | SLC5A1 (0.78) | SLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489226-B1 | INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 | LEXICON PHARMACEUTICALS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-2925735-B1 | INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 | LEXICON PHARMACEUTICALS INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9688710-B2 | Inhibitors of sodium glucose cotransporter 1 | LEXICON PHARMACEUTICALS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160326205-A1 | INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-11-10 | — | — | US | disclosed |
| US-9200025-B2 | Inhibitors of sodium glucose cotransporter 1 | LEXICON PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140309178-A1 | INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 | LEXICON PHARMACEUTICALS, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2014081660-A1 | INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 | LEXICON PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309178-A1 | INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 | SLC5A1, SLC5A2, SLC2A1 | SLC5A1 1/4885SLC5A2 2/4885 |
| US-20160326205-A1 | INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 | SLC5A1, SLC5A2, SLC2A1 | SLC5A1 1/4885SLC5A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.